Equity Overview
Price & Market Data
Price: $1.61
Daily Change: $0.00 / 0.00%
Range: $0 - $0
Market Cap: $31,035,970
Volume: 0
Performance Metrics
1 Week: 18.38%
1 Month: 28.80%
3 Months: -3.01%
6 Months: -85.40%
1 Year: -84.65%
YTD: -86.04%
Company Details
Employees: 5
Sector: Health technology
Industry: Biotechnology
Country:
Details
OSR Holdings, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Switzerland, and South Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma that is in phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1. It is also developing design-augmented (DA) biologics comprising DRT-102, a clinical-stage asset for spinal fusion; and DRT-101, a pre-clinical stage asset for osteoarthritis. In addition, the company distributes neurovascular intervention medical device and systems. OSR Holdings, Inc. is based in Bellevue, Washington.